Choose your country
Log in to Vikan.com
Requesting a password reset - we will generate a new password and email it to you
This site is optimised to run in horisontal view. Please rotate your device before continuing.
In 2018, the Foundation again received many applications for research funding.
Among those approved were projects from the Clinical Immunological Department at Aalborg University Hospital and from the Department of Public Health at the University of Copenhagen.
Exosomes are one of the several types of cell-derived vesicles now recognized as good potential markers of several human diseases, including cancer. However, their use in practical diagnostic tests requires a reliable way to effectively identify their presence, and to do so quickly and at scale.
The funding from the Vissing Foundation to the Clinical Immunological Department at Aalborg University Hospital was for the expansion and further development of the Extracellular Vesicle (EV) Array technology, which has already proven to have considerable diagnostic potential for treating lung cancer.
An EV Array consists of a microchip capable of detecting and identifying extracellular vesicles in biological fluids, and of determining their concentration. The department wants to invest in a specialised micro-array printer that can print these chips in multiples.
This will enable researchers to intensify their efforts with the same resources, and to bring this important diagnostic tool to a level where it can easily be used in ordinary medical contexts and laboratories. The aim is to help identify the presence of cancer cells as early as possible, and thus improve the positive effect of key treatments.
The funding from the Vissing Foundation to the Department of Public Health at the University of Copenhagen was for a project configured to improve how socially vulnerable patients with type 2 diabetes can access and interact with the public healthcare system, and benefit from the resources and treatments available there. The study will help general practitioners and nurses at medical practices deal more effectively with patients who suffer from type 2 diabetes.
It also involves identifying the most suitable and effective ways for the many specialists and organisations in primary as well as secondary healthcare to collaborate, in order to help redress some of the documented social inequalities that often seem to arise when this particular group of patients encounters the public healthcare system.
The project involves collaboration with a wide spectrum of research bodies, hospitals, medical practitioners and patients, as the first step towards effective intervention to improve quality of life for socially vulnerable patients with type 2 diabetes.